# Duration of Use of Highly Effective Reversible Contraception

> **NCT02414919** · — · COMPLETED · sponsor: **Bayer** · enrollment: 13880 (actual)

## Conditions studied

- Pregnancy

## Interventions

- **DRUG:** Mirena (Levonorgestrel IUS, BAY86-5028)
- **DRUG:** ParaGard
- **DRUG:** Implanon/Nexplanon

## Key facts

- **NCT ID:** NCT02414919
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-01
- **Primary completion:** 2016-03-28
- **Final completion:** 2016-03-28
- **Target enrollment:** 13880 (ACTUAL)
- **Last updated:** 2017-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414919, "Duration of Use of Highly Effective Reversible Contraception". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02414919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*